The efficacy and safety of a Unani pharmacopoeal formulations-raughan kahu in Sahar (Insomnia): A preliminary study

Abstract

In demographical studied, Out of 100 patients of Sahar (Insomnia), 35 (35.00%) were male and 65 (65.00%) female and female have higher incidence than male. The greater incidence of duration of the disease observed in 73 (73.00%) is 7-days-3 month than 34 (34.00%) 6-months to 2 years. Higher incidence of average social status patients had been observed 73 (73.00%) than poor 20 (20.00%) followed by good social status 07 (7.00%). Greater incidence of non-vegetarian 91 (91.00%) patients had been observed than vegetarian 09 (9.00%) (Table-1). Middle income group had more incidence of Sahar (Insomnia) 65 (65.00%) than lower income group 31 (31.00%) followed by higher income group 04 (4.00%) (Table-1). Non-smoker patients had more incidences 97 (97.00%) than smokers 03 (3.00%). Non-chewing habit Patient had more incidence 97 (97.00%) than chewing 03 (3.00%). According to present history patients who had difficulty in sleep had more incidences 69 (69.00%) than staying sleep 11 (11.00%) patients. Past history of patients of no history had more incidence 92 (92.00%) than constipation and indigestion and hypertension 02 (2.00%) followed by Insomnia, difficulty in sleep and khafkhan 01 (1.00%) patients. The higher incidence of temperament was found more in Balghami (Phlegmatic) temperament patients 94 (94.00%) than Damavi (Sanguine) 05 (5.00%) followed by safravi (bilious) 01 (1.00%) (Table-1). In Clinical assessment Insomnia Severity Index (ISI), when Unani pharmacopeial formulation Raughan Kahu (liquid oil) was locally applied (1.0 ml/day) to the patients for a period of 7-days. A significant reduction 27.11% (p